144P Mapping of clinically relevant antibody-drug conjugates targets by RNA sequencing in primary inoperable high-grade serous ovarian carcinoma before and after NACT in the NeoPembrOV/GINECO trial
Antibody–drug conjugates (ADCs) are an expanding therapeutic class in ovarian cancer (OC), with mirvetuximab soravtansine targeting FRα as the only approved ADC. Several other ADCs, directed against TROP2, CLDN6, CDH6, ERBB2, B7-H4, MSLN, F3 (Tissue Factor), MUC16 (CA125), and NaPi2b, are under clinical evaluation. Understanding how these targets behave before and after neoadjuvant chemotherapy (NACT) and across tumor sites is essential for optimal ADC selection and sequencing and for avoiding unnecessary re-biopsies.
Authors
- O. Le Saux
- L. Venat–Bouvet
- J. Meunier
- E. Kalbacher
- F. Joly Lobbedez
- O. Derbel
- A Martinez
- M. Martinez
- M. Ardin
- M. Leheurteur
- N. Cloarec
- O. Collard
- S.C. Fieuws
- P-A. Just
- M-A. Mouret-Reynier
- B. Hanvic
- A-M. Savoye
- F. Priou
- I.L. Ray-Coquard
- L. Bengrine Lefevre
Institutions
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Centre Georges François Leclerc (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Clinique Saint Jean (BE)
- Centre Léon Bérard (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Centre François Baclesse (FR)
- Hôpital Rangueil (FR)
- Centre Jean Perrin (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Hôpital Privé Jean Mermo (FR)
- Laboratoire National Henri Becquerel (FR)
- Centre Hospitalier Départemental Vendée (FR)
- Hôpital Privé Jacques Cartier (FR)
- Institut Jean Godinot (FR)
- Hôpital Dupuytren (FR)
- Hôpital de la Timone (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108191
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00